Fig. 4: PRMT3 enhances PD-L1 expression in tumors.
A KEGG analysis revealed the top 30 signaling pathways by utilizing RNA-seq data obtained from tumor tissues of Prmt3f/f and Prmt3LKO mice. n = 3 in each group for RNA-seq analysis. Differentially expressed genes were selected using a significance q value (q < 0.05), with a fold-change cut-off of 2 for upregulation and 0.5 for downregulation. B GSEA was performed for PD-1 Signaling and Co-stimulation by the CD28 family pathway using RNA-seq data. C A heatmap of tumor-associated immune checkpoint molecules expression profile based on GSEA. D Tumor-associated immune checkpoint molecules were detected by RT-PCR in tumor tissues of Prmt3f/f and Prmt3LKO mice. n = 7 in each group. **P < 0.01, ***P < 0.001, n.s, no significant difference. E Expression levels of Pdl1 were examined by immunoblotting in tumor tissues of Prmt3f/f and Prmt3LKO mice. F Expression levels of Prmt3 and Pdl1 determined using immunohistochemical staining. Scale bars, 50 μm. Right panel: Semi-quantitative analysis of Pdl1 positive staining in tumors. n = 7 in each group. **P < 0.01. G Expression of PD-L1 in Huh7 xenografts derived from nude mice treated with SGC707 was measured by RT-PCR (left) and immunoblotting (right). n = 7 in each group. **P < 0.01. H Expression of Pdl1 in Hepa1-6 cells with Prmt3 deletion was detected by RT-PCR (left) and immunoblotting (right). **P < 0.01. I Expression of Pdl1 in Hepa1-6 cells with Prmt3 overexpression were detected by RT-PCR (left) and immunoblotting (right). *P < 0.05, **P < 0.01, ***P < 0.001. J Expression of PD-L1 in Huh7 cells with PRMT3 overexpression was detected by RT-PCR (left) and immunoblot analysis (right). *P < 0.05, **P < 0.01. The data are presented as mean ± SD, and the statistical tests were all two-tailed.
